摘要
本研究探讨血清乳酸脱氢酶(LDH)、β2微球蛋白(β2-MG)及血管内皮生长因子(VEGF)水平检测对非霍奇金淋巴瘤(NHL)的临床意义。选择我院2010年1月至2011年12月期间收治的初治NHL患者58例为研究组,另选取同期入院参加体检的58例健康体检者为对照组。采用生物化学方法测定血清LDH水平,采用酶联免疫吸附法测定血清β2-MG和VEGF水平,超过正常值范围判断为该指标阳性。结果表明,与正常对照组相比,NHL患者的LDH、β2-MG、VEGF水平均显著升高,差别均具有统计学意义(P<0.05)。在NHL组患者中,不同病理分型和临床分期患者LDH与VEGF水平变化显著。与低度恶性患者相比,中度恶性与高度恶性患者的LDH与VEGF水平明显提高,差异具有统计学意义(P<0.05)。与临床Ⅰ期患者相比,临床Ⅱ、Ⅲ及Ⅳ期患者血清LDH与VEGF水平明显提高,差异具有统计学意义(P<0.05)。在NHL组58例患者中,LDH阳性30例,占51.72%,β2-MG阳性39例,占67.24%,VEGF阳性29例,占50.00%。结论:血清LDH、β2-MG、VEGF水平检测对NHL具有一定的临床意义。
The study was aimed to investigate the clinical significance of serum lactate dehydrogenase(LDH),β2-microglobulin(β2-MG) and vascular endothelial growth factor(VEGF) detection in non-Hodgkin′s lymphoma(NHL) patients.58 newly diagnosed NHL patients from January 2010 to December 2011 in our hospital were selected as the study group(NHL group) and 58 healthy individuals were selected at the same time as a control group.Serum LDH level was determined by a biochemical method,while β2-MG and VEGF levels were determined by enzyme-linked immunosorbent assay.The results showed that as compared with control group,the LDH,β2-MG and VEGF levels in NHL group were significantly higher(P〈0.05).In NHL group,the LDH and VEGF levels at different pathological types and clinical stages changed remarkably.Compared with low grade patients,the LDH and VEGF levels of intermediate grade and high grade patients were significantly higher(P〈0.05).As compared with patients at stage Ⅰ,the LDH and VEGF levels of patients at stage Ⅱ,Ⅲ and Ⅳ increased significantly(P〈0.05).Out from 58 cases in NHL group,30 cases(51.72%) showed LDH-positive,39 cases(67.24%) showed β2-MG positive and 29 cases(50.00%) showed VEGF-positive.It is concluded that some significant changes of serum LDH,β2-MG and VEGF appears in NHL patients,detection of these 3 tumor marker levels may be help to clinically grading patients with NHL.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2012年第3期608-610,共3页
Journal of Experimental Hematology
关键词
非霍奇金淋巴瘤
乳酸脱氢酶
Β2微球蛋白
血管内皮生长因子
non-Hodgkin′s lymphoma
lactate dehydrogenase
β2-microglobulin
vascular endothelial growth factor